Safety profile of dalfampridine extended release in multiple sclerosis: 5-year postmarketing experience in the United States

References

• LaRoccaNGImpact of walking impairment in multiple sclerosis: perspectives of patients and care partnersPatient20114318920121766914
   PubMedGoogle Scholar
• GoodmanADBrownTRKruppLBSustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trialLancet2009373966573273819249634
   PubMed Web of Science ®Google Scholar
• GoodmanADBrownTREdwardsKRA phase 3 trial of extended release oral dalfampridine in multiple sclerosisAnn Neurol201068449450220976768
   PubMed Web of Science ®Google Scholar
• Ampyra^® (dalfampridine) extended release (ER) tablets [prescribing information]New YorkAcorda Therapeutics, Inc.2014
   Google Scholar
• DunnJBlightADalfampridine: a brief review of its mechanism of action and efficacy as a treatment to improve walking in patients with multiple sclerosisCurr Med Res Opin20112771415142321595605
   PubMed Web of Science ®Google Scholar
• NicolettiASofiaVBiondiREpilepsy and multiple sclerosis in Sicily: a population-based studyEpilepsia200344111445144814636354
   PubMed Web of Science ®Google Scholar
• PoserCMBrinarVVEpilepsy and multiple sclerosisEpilepsy Behav20034161212609222
   PubMed Web of Science ®Google Scholar
• HautSRBienenEJMillerAClinical overview of the seizure risk of dalfampridineExpert Opin Drug Saf201211465165722703551
   PubMed Web of Science ®Google Scholar
• CornblathDRBienenEJBlightARThe safety profile of dalfampridine extended release in multiple sclerosis clinical trialsClin Ther20123451056106922497693
   PubMed Web of Science ®Google Scholar
• GoodmanADBethouxFBrownTRLong-term safety and efficacy of dalfampridine for walking impairment in patients with multiple sclerosis: results of open-label extensions of two Phase 3 clinical trialsMult Scler201521101322133125583832
   PubMed Web of Science ®Google Scholar
• ErikssonMBen-MenachemEAndersenOEpileptic seizures, cranial neuralgias and paroxysmal symptoms in remitting and progressive multiple sclerosisMult Scler20028649549912474990
   PubMed Web of Science ®Google Scholar
• Food and Drug AdministrationSupplemental Approval, Release REMS Requirement, REMS Assessment AcknowledgmentSilver Spring, MDFood and Drug Administration2013 http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2013/022250Orig1s008ltr.pdfAccessed November 4, 2015
   Google Scholar
• JaraMBarkerGHenneyHR3rdDalfampridine extended-release tablets: one year of post-marketing safety experience in the United StatesNeuropsychiatr Dis Treat2013936537023662056
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration [homepage on the Internet]FDA Adverse Event Reporting System (FAERS) Available from: http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/Accessed November 4, 2015
   Google Scholar
• JaraMAderaMAdedejiAHenneyHCarrazanaEDalfampridine Extended Release Tablets: Safety Profile After 2 Years of Post-marketing Experience in the United States [abstract]Mult Scler
   Google Scholar
• BertheCOngagnaJCCourtoisSProlonged-release Fampridine post-marketing experience in Alsace, France [abstract]Neurology201584SupplP1.126
   Google Scholar
• JaraMSidovarMFHenneyHR3rdPrescriber utilization of dalfampridine extended release tablets in multiple sclerosis: a retrospective pharmacy and medical claims analysisTher Clin Risk Manag2014111725565851
   PubMed Web of Science ®Google Scholar
• KantorDChancellorMBSnellCWHenneyHR3rdRabinowiczALAssessment of confirmed urinary tract infection in patients treated with dalfampridine for multiple sclerosisPostgrad Med2015127221822225560174
   PubMed Web of Science ®Google Scholar
• HuppertsRLyckeJShortCProlonged-release fampridine and walking and balance in multiple sclerosis: randomized MOBILE studyMult Scler Epub2015428
   Google Scholar
• MatsudaPNShumway-CookABamerAMJohnsonSLAmtmannDKraftGHFalls in multiple sclerosisPM R20113762463221777861
   PubMedGoogle Scholar
• GunnHJNewellPHaasBMarsdenJFFreemanJAIdentification of risk factors for falls in multiple sclerosis: a systematic review and meta-analysisPhys Ther201393450451323237970
   PubMed Web of Science ®Google Scholar
• NilsagardYGunnHFreemanJFalls in people with MS-an individual data meta-analysis from studies from Australia, Sweden, United Kingdom and the United StatesMult Scler20152119210024948687
   PubMed Web of Science ®Google Scholar
• HowardRSWilesCMHirschNPLohLSpencerGTNewsom-DavisJRespiratory involvement in multiple sclerosisBrain1992115Pt 24794941606478
   PubMed Web of Science ®Google Scholar
• van KlaverenRBuyseTVan De GaerLMeekersJRochetteFDemedtsMMicturitional disturbances are associated with impaired breathing control in multiple sclerosisChest199911561539154510378546
   PubMed Web of Science ®Google Scholar
• FarhatMRLoringSHRiskindPWeinhouseGDisturbance of respiratory muscle control in a patient with early-stage multiple sclerosisEur Respir J20134161454145623728406
   PubMed Web of Science ®Google Scholar
• MarrieRAReiderNCohenJA systematic review of the incidence and prevalence of cardiac, cerebrovascular, and peripheral vascular disease in multiple sclerosisMult Scler201521331833125533300
   PubMed Web of Science ®Google Scholar
• MarrieRARudickRHorwitzRVascular comorbidity is associated with more rapid disability progression in multiple sclerosisNeurology201074131041104720350978
   PubMed Web of Science ®Google Scholar
• SiegertRJAbernethyDADepression in multiple sclerosis: a reviewJ Neurol Neurosurg Psychiatry200576446947515774430
   PubMed Web of Science ®Google Scholar
• ManouchehriniaATanasescuRTenchCRConstantinescuCSMortality in multiple sclerosis: meta-analysis of standardised mortality ratiosJ Neurol Neurosurg Psychiatry Epub201552
   Google Scholar
• WoodRACamargoCAJrLiebermanPAnaphylaxis in America: the prevalence and characteristics of anaphylaxis in the United StatesJ Allergy Clin Immunol2014133246146724144575
   PubMed Web of Science ®Google Scholar
• Food and Drug AdministrationNDA ApprovalSilver Spring, MDFood and Drug Administration2010 Available from: http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2010/022250s000ltr.pdfAccessed November 4, 2015
   Google Scholar
• JaraMGauvinDVCaggianoAOWalterBParryTJHenneyHEvaluation of the Abuse Potential of Dalfampridine Extended Release Tablets (P565)28th Congress of the European Committee for Treatment and Research in Multiple SclerosisOctober 10–13; 2012Lyon, France
   Google Scholar